Latest Healthcare It News

Austco Healthcare delivered record FY26 revenue and statutory profit, with stronger margins, cash generation and a modest recovery in contracted orders entering the new financial year. The company is pairing that momentum with further reseller consolidation, including the $2.88 million acquisition of Medical Communications Systems.

Emyria has presented its regulated Australian psychedelic-treatment experience to the US FDA, putting clinical delivery systems rather than drug development at the centre of its US ambitions. The appearance raises the company’s profile, but does not yet disclose regulatory approval, a commercial agreement or a financial commitment.

Paragon Care has lined up an on-market buy-back of up to 82.8 million shares, worth about $10.8 million at the latest closing price, while its employee trust can acquire a further 23.9 million shares. The transactions give the healthcare group two sizeable tools for managing its capital and incentive plans, although neither maximum is guaranteed to be completed.

Lumos Diagnostics has increased live FebriDx sites to 215 and moved two additional top 100 US urgent care groups into network rollout across more than 40 sites. Two further health-system-owned groups are validating the test across more than 45 sites, but the announcement does not disclose contract values or guaranteed purchase volumes.

Regal Asian Investments delivered a 3.2% net portfolio return in August, lifting its 12-month performance to 36.4% despite continued volatility across Asian equities. The listed investment company’s shares ended the month at a 14.3% discount to post-tax NTA, while its buy-back and fully franked dividend continued.

HealthCo Healthcare & Wellness REIT says lenders have backed the proposed transfer of operations at 10 Healthscope hospitals owned by HCW and its unlisted fund. The transaction remains subject to customary approvals, but Healthscope has paid all rent due through September 2026.

Synertec has identified ANSTO as the client behind its $45.5 million engineering contract, with about $36 million of revenue expected during the first 26 months. The project could improve FY27 revenue, but the company has not yet revised its guidance.

Australian United Investment Company’s profit surged after its merger with Diversified United Investment, but the headline result was dominated by a one-off acquisition gain. Underlying profit rose 19.9%, while AUI expanded its portfolio to about A$3.1 billion and declared fully franked dividends totalling 28 cents per share.

Marlin Global delivered a 3.0% gross performance return in August, beating its benchmark as software holdings rebounded sharply. The Fisher Funds-managed portfolio is also preparing to exit some investments and add businesses in three sectors.

Kingfish’s adjusted NAV rose 1.2% in August, broadly matching the NZX benchmark as Vista, Fisher & Paykel Healthcare and Delegat delivered the strongest portfolio gains. The fund still trades at a 7.5% discount to NAV, while its one-year shareholder return remains negative.

EBR Systems has secured ISO 13485 certification for its new Santa Clara manufacturing site, paving the way for a 500% increase in WiSE System production pending FDA approval expected by year-end.

EMVision is progressing its CRC-P funded Regional Benefits Study to evaluate the emu™ bedside brain scanner in remote hospitals, aiming to speed up stroke diagnosis where CT access is limited. Site visits are complete, and protocol development is underway, with relevance extending to similar rural hospitals in the US.